Upbeat forecast from Lilly on weight loss drugs adds to Novo Nordisk gloom as it foresees steep drop in sales
Novo blames pricing deal with Donald Trump for downbeat outlook for year ahead but it also faces greater patent expiry issues than its US rival























































